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Abstract
Pattern recognition receptors and receptors for pro-inflammatory cytokines provide critical signals to drive the
development of protective immunity to infection. Therefore, counter-regulatory pathways are required to ensure that
overwhelming inflammation harm host tissues. Previously, we showed that lipoxins modulate immune response during
infection, restraining inflammation during infectious diseases in an Aryl hydrocarbon receptor (AhR)/suppressors of cytokine
signaling (SOCS)2-dependent-manner. Recently, Indoleamine-pyrrole 2,3- dioxygenase (IDO)-derived tryptophan metabo-
lites, including L-kynurenine, were also shown to be involved in several counter-regulatory mechanisms. Herein, we
addressed whether the intracellular molecular events induced by lipoxins mediating control of innate immune signaling are
part of a common regulatory pathway also shared by L-kynurenine exposure. We demonstrate that Tumor necrosis factor
receptor-associated factor (TRAF)6 – member of a family of adapter molecules that couple the TNF receptor and interleukin-
1 receptor/Toll-like receptor families to intracellular signaling events essential for the development of immune responses –
is targeted by both lipoxins and L-kynurenine via an AhR/SOCS2-dependent pathway. Furthermore, we show that LXA4- and
L-kynurenine-induced AhR activation, its subsequent nuclear translocation, leading SOCS2 expression and TRAF6 Lys47-
linked poly-ubiquitination and proteosome-mediated degradation of the adapter proteins. The in vitro consequences of
such molecular interactions included inhibition of TLR- and cytokine receptor-driven signal transduction and cytokine
production. Subsequently, in vivo proteosome inhibition led to unresponsiveness to lipoxins, as well as to uncontrolled pro-
inflammatory reactions and elevated mortality during toxoplasmosis. In summary, our results establish proteasome
degradation of TRAF6 as a key molecular target for the anti-inflammatory pathway triggered by lipoxins and L-kynurenine,
critical counter-regulatory mediators in the innate and adaptive immune systems.
Citation: McBerry C, Gonzalez RMS, Shryock N, Dias A, Aliberti J (2012) SOCS2-Induced Proteasome-Dependent TRAF6 Degradation: A Common Anti-
Inflammatory Pathway for Control of Innate Immune Responses. PLoS ONE 7(6): e38384. doi:10.1371/journal.pone.0038384
Editor: Guillermo H. Giambartolomei, National Council of Sciences (CONICET), Argentina
Received December 15, 2011; Accepted May 4, 2012; Published June 5, 2012
Copyright:  2012 McBerry et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research results presented here were funded by National Institutes of Health (NIH) grants AI075038 and AI078969 and by a supplement for C.M.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: julio.aliberti@cchmc.org
. These authors contributed equally to this work.
Introduction
Lipoxins (LX) are trihydroxytetraene-containing arachidonic
acid mediators that down-modulate and promote the resolution of
inflammatory processes [1–7]. Lipoxins play a relevant counter-
regulatory role in a growing list of mouse models of infectious
diseases, including Mycobacterium tuberculosis and Toxoplasma gondii
[2,3,7,8]. Similarly, deficient LX-mediated counter-regulation has
been linked to the pathogenesis of inflammatory diseases such as
severe asthma [9], cystic fibrosis lung disease [3] and periodontal
disease [7]. Lipoxin A4 (LXA4) is the most prominent mediator of
this class. Although it is still not clear how these mediators operate
at the intracellular level, LX analog administration has showed
beneficial effects in several rodent models of inflammatory
pathology suggesting a therapeutic promise for specific harnessing
of the biological activities of these potent lipid mediators. Their
molecular mechanism(s) of action remain under-defined, however.
Tryptophan catabolism into kynurenine by IDO functions as a
counter-regulatory pathway mediating potent suppression of
T cell responses in vitro and in vivo [10], however the molecular
mechanisms remain to be fully defined. Inhibition of T cell
responses by IDO-expressing dendritic cells is thought to play an
important physiological role in suppressing the development and
expression of autoimmune and allergic diseases [10]. Moreover,
IDO is expressed by many tumors, as well as by a subpopulation of
dendritic cells in tumor-draining lymph nodes. Consequently,
IDO inhibition can rescue anergic, tumor antigen-specific T cell
effector function, inhibiting tumor growth in mouse models
[11,12]. Sustained IDO activation is also thought to be an
important cause of immunosuppression in HIV infection [13].
During toxoplasmosis, it has been shown that IDO activation is
critical for controlling intracellular pathogen multiplication,
probably via tryptophan starvation [14]. IDO expression can be
regulated in diverse cell types by pathogen- and host-derived
inflammatory signals, including pro-inflammatory cytokines (i.e.
IFN-c), Toll-like receptor ligands (e.g., lipopolysaccharide), and
interactions between immune cells (e.g., the engagement of
costimulatory molecules on antigen presenting cells by CTLA-4)
[10]. The potential for therapeutic exploitation of physiological
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therapeutic targeting of pathophysiological IDO activity (in cancer
and HIV) is currently under active investigation.
IDO-derived tryptophan metabolites were previously shown to
interact with the nuclear receptor, aryl hydrocarbon receptor
(AhR) [15–17]. AhR is present in the cytoplasm associated with
chaperones, such as HSP90. Upon ligand binding, AhR is released
from HSP90 and pairs with the nuclear transporter – ARNT –
translocates to the nucleus and activates gene transcription of
dioxin-responsive elements (DRE) sequences within promoter
regions of several genes, including cytochrome p450 gene family
members, genes involved in control of cell cycle and cell death,
including SOCS2. We recently showed that SOCS2 is an
important AhR-dependent intracellular mediator of the anti-
inflammatory actions of lipoxins during in vivo T. gondii infection
[18]. Although there is previous evidence for lipoxin triggering of
AhR [19], such results have not been further confirmed to date.
SOCS proteins are known to inhibit receptor-mediated signal
transduction via several pathways, including inhibition of tyrosine
phosphorylation by allosteric blockage (e.g., of JAK proteins) and
induction of proteasomal degradation by promoting polyubiqui-
tinylation (e.g., of STAT proteins) [20].
Taken together there is strong evidence that both lipoxins and
the tryptophan metabolite L-kynurenine share a common
intracellular pathway via induction of SOCS2. The present study
was aimed to define the molecular target(s) and mechanism(s) of
action of lipoxin- and L-kynurenine-induced SOCS2. The results
presented here demonstrate that lipoxins and L-kynurenine induce
SOCS2-dependent ubiquitinylation and proteasomal degradation
of TRAF6, hindering pro inflammatory cytokine expression by
dendritic cells. Further, these results indicate that the proteosome-
dependent pathway is triggered by lipoxins to modulate innate
immune signaling and is critical to restrain the in vivo
inflammatory responses during infection with T. gondii.
Results
LXA4 and L-kynurenine Inhibit Pro-inflammatory
Cytokine Responses in vitro
Considering our previous finding that LXA4 exposure triggers
AhR-dependent SOCS2 expression that tryptophan metabolites,
including L-kynurenine trigger AhR, we raised the question
whether both LXA4 and L-kynurenine could initiate a similar anti-
inflammatory profile in dendritic cells. Therefore we tested if pre-
exposure to LXA4 (blue bars) or L-kynurenine (red bars) could
inhibit in a SOCS2-dependent manner, the pro-inflammatory
response after incubation with a panel of microbial/endogenous
ligands (microbial products, CD154, IL-1b). Our results show
(Figures 1A through E) that both mediators tested caused a broad
inhibitory action effectively blocking several inter-related pro-
inflammatory pathways, including TLR/MyD88, TLR/TRIF,
IL-1R/MyD88, CD40/CD154. Moreover, SOCS2 was required
for this inhibitory effect for both LXA4 and L-kynurenine (hatched
bars – SOCS2-KO versus solid bars – WT DC’s). This set of
results led us to suggest that LXA4 and L-kynurenine share a
common inhibitory target and, possibly, an intracellular pathway
that depends on the expression of SOCS2.
L-kynurenine Induces SOCS2 Expression by Mouse
Spleen-derived Dendritic Cells
We have previously shown that LXA4 triggered an AhR-
dependent SOCS2 expression in mouse spleen-derived dendritic
cells. Given the results shown above, that the inhibitory actions
of L-kynurenine overlapped those seen when cells were exposed
to LXA4 and that SOCS2-deficient cells failed to show L-
kynurenine-mediated inhibition of pro-inflammatory cytokine
production, we asked whether there is significant induction of
socs2 gene expression in dendritic cells exposed to L-kynurenine.
As can be seen in Figure 2, L-kynurenine induced significant up-
regulation of SOCS2 message levels. Importantly, SOCS2
induction by L-kynurenine was completely abolished in AhR-
deficient cells. 6-formylindolo[3,2-b] carbazole (FICZ), a trypto-
phan metabolite used as a prototypical AhR ligand [21], also
induced socs2 gene expression in an AhR-dependent manner.
Taken together, this set of results clearly indicates that AhR is a
component of the pathway involved in SOCS2 induction by L-
kynurenine in dendritic cells, in agreement with our previous
experimental observations with LXA4.
LXA4 and L-kynurenine Induce AhR Nuclear Translocation
Prototypical AhR ligands, such as dioxins, are thought to
migrate through the cellular membrane and associate with AhR,
which uncouples from chaperones, such as HSP90 [22]. Follow-
ing, heterodimerization of AhR and ARNT takes place at the
nuclear membrane, mediating its nuclear translocation [23]. Once
in the nucleus, those heterodimers are thought to bind to specific
promoter sequences, termed DRE [24]. In order to evaluate
whether either LXA4 or L-kynurenine exposure initiates nuclear
translocation of AhR, we performed ImageStream analysis of
spleen-derived CD11c+ dendritic cells (Figure 3) after 2.5-hrs
incubation in the presence of medium alone (Figure 3A), LXA4
(Figure 3B), L-kynurenine (Figure 3C) and the prototypical AhR-
ligand, FICZ (Figure 3D). The results showed evident nuclear
translocation in all groups (summarized in figure 3E), except for
control cells incubated in medium alone. To further establish AhR
as a molecular component of this shared anti-inflammatory
pathway, we performed ImageStream analysis examining AhR/
ARNT co-localization. Figure 4 indicates the frequency of AhR/
ARNT co-localization among spleen-derived CD11c+ cells
exposed to medium alone, LXA4, L-kynurenine and FICZ
(Figure 4A–D). The results indicate a consistent up-regulation
around 2 hrs after stimulation of AhR/ARNT heterodimers in
cells treated with LXA4, L-kynurenine and FICZ, but not in
control medium group (Summarized in figure 4E). In summary,
the results shown here suggest that a common intracellular
pathway is shared by both LXA4 and L-kynurenine; upon AhR
ligand stimulation, nuclear receptor translocation occur leading to
its subsequent dimerization with ARNT, in agreement with
previous molecular interactions described for AhR [21–25].
LXA4 and L-kynurenine Trigger DRE-dependent Gene
Expression in Dendritic Cells
The results shown so far delineate the events triggered after
exposure to both LXA4 and L-kynurenine in mouse spleen-derived
dendritic cells that ultimately lead to inhibition of cytokine
production in response to pro-inflammatory stimuli. To do so,
induction of SOCS2 via activation of AhR seems to be required.
Moreover, both ligands can initiate AhR heterodimerization with
ARNT and subsequent nuclear translocation. As seen with
exogenous AhR ligands, such as dioxins, once the AhR/ARNT
is localized in the nucleus, it binds to DRE sequences found within
several gene promoter regions initiating a transcription program
that includes several genes, including SOCS2. We therefore,
pursued to examine whether LXA4 and L-kynurenine triggers
AhR-dependent DRE-driven gene expression in vitro and in vivo.
To do so, we took advantage of a transgenic mouse model in
which beta-galactosidase is expressed under a promoter region
containing three tandem DRE motifs [25]. This model animal
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toxicological responses to exposure to environmental pollutants,
such as dioxins. In order to determine which dendritic cell subsets
up-regulate beta-galactosidase enzymatic activity, we used an
adapted flow cytometry method, in which cleavage of the substrate
by beta-galactosidase releases a fluorescent marker that can be
detected by the cytometer. As shown in figure 5 (in vitro
stimulated, purified spleen-derived dendritic cells), exposure to
LXA4, L-kynurenine and FICZ induced up-regulation of DRE-
driven beta-galactosidase enzymatic activity, which is evidenced
by the increased detection of the fluorescent metabolite. LXA4
produced a steady induction of beta-galactosidase, as early as 1 hr
after stimulation up to 12 hrs thereafter. On the other hand, both
L-kynurenine and FICZ peaked beta-galactosidase activity at 2
and 4 hrs, declining afterwards (not shown). Suggesting that a
potential limiting factor for AhR-dependent gene induction, i.e.
AhR/ARNT dissociation, might have differentiated rates among
several ligands.
L-kynurenine and LXA4 Triggers SOCS2-dependent
TRAF6 Poly-ubiquitinylation and Proteasomal
Degradation in Mouse Spleen-derived Dendritic Cells
So far, our data support a common regulatory pathway initiated
by exposure to LXA4 or L-kynurenine. The intracellular events
identified here indicate that AhR is one of the intracellular
signaling elements. Ligand exposure triggered its dimerization
with ARNT, nuclear translocation and subsequent triggering of
DRE promoter carrying genes (which includes socs2). Importantly,
the anti-inflammatory actions of both ligands were shown to be
dependent on SOCS2. Another critical overlap among the effects
of both ligands is the broad suppressive effect over TRAF6-
dependent responses (i.e. TLR, IL-1R). Therefore, we hypothe-
sized that the AhR-triggered SOCS2 activity would be targeting
TRAF6 to inhibit of signal transduction after pro-inflammatory
receptor activation. To address this, we considered two main
mechanisms by which SOCS proteins regulate signaling: allosteric
blockage and proteasomal degradation of polyubiquitinylated
targets. In order to test this hypothesis, we exposed spleen-derived
dendritic cells to medium alone, LXA4, L-kynurenine or IL-10 (a
immunomodulatory mediator that is SOCS2-independent) after
several time points and tracked TRAF6 status by immune-
precipitation/western blot as well as intracellular flow cytometry
analysis (Figure 6). We observed that immune-precipitation of
TRAF6 co-precipitated Lys47-linked poly-ubiquitin chains after
exposure to LXA4 (Lx) and L-Kynurenine (Ky) but low levels in
medium alone (M) or after exposure to IL-10 (10). Interestingly, no
detection of Lys63-linked poly-ubiquitin chains was found under
the conditions tested here (Figure 6A). Importantly, while WT
DCs showed co-precipitation of TRAF6 with Lys47-linked poly-
ubiquitin chains, SOCS2-deficient cells showed only moderate co-
precipitation of Lys47-linked poly-ubiquitin chains with TRAF6
after IL-10, but not after LXA4 or L-kynurenine, suggesting that
the cytokine may target TRAF6 through a SOCS2-independent
pathway (Figure 6A). Figure 6B shows that detection of TRAF6 is
significantly reduced at 20 hrs after LXA4 or L-kynurenine
exposure in vitro. To further confirm that LXA4 and L-
kynurenine trigger a proteasomal pathway that targets TRAF6,
we pre-exposed spleen-derived dendritic cells with a proteasome
inhibitor, the peptide PR11 (low-toxicity, reversible blocker of the
ubiquitin recognition domains of the proteasome [26]). Figure 6C
shows that the intracellular levels of TRAF6 are partially
preserved when cells were exposed to PR11 prior to LXA4.T o
further confirm this set of findings through an independent
technique (intracellular flow cytometry TRAF6 staining) we
exposed WT DCs to LXA4 or IL-10 for 4 hrs and performed
intracellular staining for TRAF6. The data shown in Figure 6D
indicate a significant decline in the TRAF6 MFI for CD11c+ cells
after LXA4, but not IL-10. Additionally, L-kynurenine drove an
AhR/SOCS2-dependent decrease of TRAF6 intracellular levels in
CD11c+ cells in a dose-dependent manner (Figure 6E). Further-
more, while control cells incubated in the presence of LXA4 or L-
kynurenine alone showed significant decrease of TRAF6 MFI,
pre-treatment with PR11rescued TRAF6 expression normal levels
(Figure 6F). IL-10 or growth hormone (Gh) – a mediator that we
have previously shown to induce SOCS2 expression in spleen-
derived DCs [18,27] – treatment did not affect the expression
levels of TRAF6 detected. On the other hand, 3-OH-kynurenine
(another tryptophan metabolite derived from IDO activity) also
caused reduced detection of TRAF6, an effect that could be only
partially restored by PR11 treatment (Figure 6F), however, in
contrast to L-kynurenine this metabolite showed increased
cytotoxicity.
Taken together, the results shown here provide compelling
evidence that AhR/SOCS2-mediated proteasomal degradation of
TRAF6 is a common pathway shared by both LXA4 and L-
kynurenine.
Figure 1. LXA4 and L-kynurenine suppress pro-inflammatory gene induction in a SOCS2-dependent manner. WT (filled symbols) or
SOCS2-KO (empty symbols) spleens were harvested and CD11c+ cells purified. Cells were incubated in the presence of medium alone (black squares)
or with LXA4 (3 nM – blue triangles) and L-kynurenine (60 mM – red circles) for 6 hrs, followed by stimulation with CD154, IL-1b, TNF, LPS, STAg or
CpG-oligos (1 mg/mL) for 4 hrs. Cells were lized, total RNA obtained and real-time RT-PCR reaction performed for the following genes: il12a (A), il12b
(B), il23p19 (C), tnf (D), il6 (E) and ifna3 (F). Data shown represents normalized values against b-actin expression levels and are representative of three
independent assays performed. Asterisks indicate statistically significant differences between the medium versus LXA4 or L-kynurenine treated
samples (p,0.05).
doi:10.1371/journal.pone.0038384.g001
Figure 2. socs2 mRNA expression in spleen-derived dendritic
cells exposed to LXA4, L-kynurenine and FICZ is AhR-depen-
dent. WT (filled bars) or AhR-deficient (empty bars) spleen-derived
dendritic cells were isolated and incubated for 4 hrs in the presence of
medium alone or with LXA4 (3 nM), L-kynurenine (60 mM) or FICZ
(4 mM). Total RNA was then obtained, followed by real-time RT-PCR for
socs2. Data shown represents expression values normalized against b-
actin expression. Asterisks indicate statistically significant differences
(p,0.05) when comparing WT vs. AhR group samples. Data shown is
representative of four independent experiments performed.
doi:10.1371/journal.pone.0038384.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38384Figure 3. LXA4 and L-kynurenine mediate AhR nuclear translocation in spleen-derived CD11c+ cells. Collagenase-digested, low-density,
spleen-derived cells were incubated in the presence of medium alone (yellow), or with FICZ (4 mM), LXA4 (3 nM) or L-kynurenine (60 mM) for 150
minutes followed by staining for CD11c, AhR and DNA (Draq5–nuclear counterstaining) and analyzed using ImageStream. Data shown indicates the
CD11c+AhR+ cells gated for analysis of Draq5+AhR+ staining overlay histograms. Cells analyzed were incubated with medium alone (A), LXA4 (B), L-
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Activity is Critical for Control of Inflammatory Responses
during in vivo Toxoplasma gondii Infection
Endogenously generated lipoxins control pro-inflammatory
responses through SOCS2 during T. gondii infection [8]. In the
absence of lipoxins or SOCS2, infection with T. gondii is lethal due
to aberrant uncontrolled inflammation [8]. We hypothesized that
TRAF6 proteasomal degradation is a downstream target for
lipoxin-mediated control of pro-inflammatory responses during in
vivo infection. We initially asked whether both AhR and SOCS2
would modulate counter-regulatory response during T. gondii
infection. Figure 7A show that AhR-deficiency, similar to what we
previously observed with SOCS2-KO mice, leads to mortality at
around 45–50 days after infection with T. gondii. Brain cyst loads
showed significantly lower counts in both SOCS2-KO and AhR-
deficient mice. Moreover, serum levels of the protective pro-
inflammatory cytokines, IL-12p70 (Figure 7C) and IFN-c
(Figure 7D) were significantly higher in both of the genetically
mutant mouse lineages after infection. Taken together, these
results establish that during in vivo T. gondii infection, lipoxin-
mediated activation of AhR and induction of SOCS2 expression
leads to a counter-regulatory pathway that inhibits excessive type 1
pro-inflammatory cytokine production in vivo.
To further establish the role of lipoxin-induced proteasomal
degradationincontrollingimmuneresponsestoinvivoinfection,we
infectedWTmicewithT.gondii,withorwithoutdailytreatmentwith
PR11, starting from day 11 after infection – a time-point previously
found to be the time at which increases in serum levels of LXA4 are
detectable [8]. At this time point, most T cell priming is thought to
have occurred. Moreover, direct testing of the effect of proteasome
inhibitiononCD8+TcellduringLCMVinfectionshowedthatsuch
treatment did not affect expansion of CD8+T cells specific for
LCMV-derived peptides (D. Hildeman, unpublished data).
Figures 7E–F shows that proteasome inhibition during T. gondii
infection mirrored the uncontrolled pro-inflammatory phenotype
seen in both 5-lipoxygenase (LO)-deficient and SOCS2-deficient
mouse strains [8,18], including: (Fig. 7E) high levels of circulating
CD4+CD3+IFN-c+Tcellsand(Fig.7F)mortalityoccurringaround
40–50 days after inoculation. Taken together, these data clearly
establish TRAF6 as critical downstream target for proteasomal
degradation mediated by endogenous lipoxin-stimulated SOCS2.
Thus, lipoxin-mediated degradation of these key pro-inflammatory
signaling adaptor proteins is essential for tight control of the innate
immune response to infection with T. gondii.
To further substantiate the biological relevance of LXA4/
SOCS2/AhR pathway in controlling pro-inflammatory response
during infection with T. gondii, we perform histopathological
analysis of the brain and liver tissues obtained from WT, SOCS2-
KO and AhR
d mice at 30 days after infection. Figures 8A–B shows
typical inflammation in chronically infected WT mice. Panel 8A
displays two parasite cysts (circles) and inflammatory infiltrate
(indicated by an arrow) which are focal and perivascular with no
significant meningitis (Figure 8B). On the other hand, brain
sections from both SOCS2-KO (Fig. 8C–D) as well as AhR
d
(Fig. 8E–F) show significantly increased and diffuse inflammatory
cell infiltrates, including atypical meningitis (Figs. 8D and F,
respectively). In addition, the liver sections from infected WT,
SOCS2-KO and AhR
d mice showed a similar trend with regard to
inflammatory cell infiltration: perivascular/focal mononuclear
infiltrates (Figs. 8G to I). In summary, this set of results provides
further support for the pivotal role of the LXA4/SOCS2/AhR
pathway in preventing damage to host tissues during the chronic
phase of T. gondii infection.
Discussion
Counter-regulation of immune responses mediated by both
lipoxins and IDO-dependent mechanisms have been found to be
relevant in a growing list of infectious, chronic inflammatory and
auto-immune diseases, including toxoplasmosis, HIV infection,
leishmaniasis, tuberculosis, cystic fibrosis, asthma and periodontitis
[14,27]. Importantly, the intracellular mechanisms by which such
relevant anti-inflammatory actions occur are poorly understood.
While several potential pathways have been suggested to explain
IDO-dependent actions [28], the intracellular mechanism of
lipoxins is still elusive. Given the common target aimed by both
ligands, we hypothesize here that a shared regulatory pathway
must take place. In fact, we show here several lines of evidence that
clearly demonstrate that both LXA4 and L-kynurenine trigger
AhR-driven SOCS2 expression, including AhR-dependent induc-
tion of SOCS2, increased co-localization of AhR with ARNT,
nuclear translocation of AhR and activation of gene expression in
a DRE-induced manner. In turn, AhR-triggered SOCS2-mediat-
ed Lys47-linked poly-ubiquitin chain ligation of TRAF6, a well-
known marker for proteasome-targeted degradation. Conversely,
pre-exposure to inhibitors of proteasome recognition of such poly-
ubiquitin chains, led to abolishment of TRAF6 degradation.
Although our data provide clear evidence of the downstream
events initiated after LXA4 and L-kynurenine exposure, the
biochemical nature of the recognition and binding to AhR is not
established yet. It has been demonstrated that AhR is found in
the cytosol associated with HSP90 in a non-active state [22]. In
the presence of dioxins, AhR is released from HSP90 and form a
stable heterodimer with the nuclear transporter ARNT. Studies
using tryptophan and its metabolites have shown their binding to
AhR, including FICZ, another commonly used prototypical
exogenous ligand for AhR [29]. Although there is no direct
evidence of L-kynurenine binding to AhR, our results indicated a
strong cause-effect correlation between the two. A parallel case
can be traced between LXA4 and AhR, where all evidence point
to a strict cause-effect relationship, no direct binding data has
been shown. One possible explanation is the volatile nature of
LXA4 and the relative low-sensitivity of the binding assays
available. Another possibility is that in both the cases of LXA4 as
well as L-kynurenine, a new molecule is generated or a
significantly modified version of the ligands reach AhR. In any
case, those unanswered questions remain to be further explored
in future studies.
Another important aspect of this pathway is the putative
formation of an ubiquitin ligase complex by SOCS2 targeting
Lys47-linked poly-ubiquitin chain ligation onto TRAF6 for
proteasome degradation. TRAF6 can be ubiquitinylated with
mono- or Lys63-linked poly-ubiquitin chains, typical markers of
activation pathways, in which ubiquitinylated TRAF6 leads to
binding to other signaling components, such as TAK6 among
others [30]. The molecular basis that determine one form
(proteasome directed) versus the other (activation associated) are
not clear at the moment. It is possible that a second component is
mediating the ubiquitin ligation changes or that TRAF6 becomes
kynurenine (C) and FICZ (D). Panel E shows a summary of the data shown in panels A–D. Data is representative of three independent experiments
performed.
doi:10.1371/journal.pone.0038384.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38384Figure 4. AhR and ARNT intracellular co-localization is induced after exposure to LXA4 and L-kynurenine. Collagenase-digested, low-
density, spleen-derived cells were incubated in the presence of medium alone (yellow), or with FICZ (4 mM), LXA4 (3 nM) or L-kynurenine (60 mM) for
150 minutes followed by staining for AhR and ARNT and analyzed using ImageStream. Data shown indicates the AhR+ARNT+ cells gated for analysis
of AhR+ARNT+ staining overlay histograms. Cells analyzed were incubated with medium alone (A), LXA4 (B), L-kynurenine (C) and FICZ (D). Panel E
shows a summary of the data shown in panels A–D. Data is representative of three independent experiments performed.
doi:10.1371/journal.pone.0038384.g004
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of post-translational modification, such as tyrosine phosphoryla-
tion – a key element for target protein recognition for SOCS
proteins. Although there are no reports on TRAF6 phosphoryla-
tion or a potential biological function associated with TRAF6
phosphorylation, it is a possible scenario that has not been
completely ruled out yet. Nevertheless, the cause-effect relation-
ship between elevated expression of SOCS2 and proteasome
degradation of TRAF6 is undeniable. Furthermore, all those
effects are strongly involved in the mediating the anti-inflamma-
tory actions mediated by both LXA4 and L-kynurenine.
A fundamental question in host-pathogen interactions is
whether the immune system is properly activated to eradicate
pathogens and if this response is appropriately controlled to
prevent damage to the host during control or elimination of
infection [27]. Microbial recognition is a critical first step that is
central to both innate and adaptive immunity. DCs signal the
presence of microbes via pattern recognition receptors such as the
Toll-like receptors (TLR) [31–34] and respond by secreting
cytokines and other effector molecules, which are critical for
immune activation and dictating the type of immune response.
During infection with T. gondii (and infections with other
intracellular pathogens) the production of IL-12, IFN-c and
TNF by DCs is essential to control pathogen growth [27,35,36].
IL-12 and TNF are potentially toxic when produced in excess;
indeed, their production is tightly regulated by a remarkably large
number of different mechanisms [1,27,32]. In toxoplasmosis, the
pro-inflammatory process is counterbalanced by the simultaneous
induction of critical, non-redundant counter-regulatory mediators,
including IL-10 and LXs [18,27]. Mice with a genetic deficiency in
LX production succumb to lethal inflammatory responses during
toxoplasmosis [8]. In turn, the biological importance and non-
redundant nature of the proteasome pathway to the mechanism of
action of LXs is underscored by the finding that proteasome
inhibition during toxoplasmosis prevents the regulatory actions of
LX, restoring TLR and cytokine receptor signaling in vivo and
causing uncontrolled pro-inflammatory cytokine production,
aberrant leukocyte infiltration and elevated mortality. Interesting-
ly, we found that during mouse toxoplasmosis, IDO did not exert
an evident immuno-regulatory function, as seen during other
infectious diseases. Instead, IDO perform a critical microbiostactic
function, possibly due to tryptophan depletion, allowing macro-
phages to prevent intracellular growth of T. gondii [14]. Therefore,
it is not feasible to examine the immune-modulation caused by
released L-kynurenine during T. gondii infection.
It has become clear in recent years that uncontrolled
inflammatory responses are central to the pathogenesis of a wide
range of diseases causing an enormous burden of morbidity and
mortality in the world at large. The results presented here suggest
that degradation of TRAF6 is a shared/redundant anti-inflam-
matory pathway that provides a promising biochemical target for
drug development aimed at modulating inflammatory processes in
these diseases.
Materials and Methods
Mice
Wild-type controls (C57BL/6) and AhR-deficient (AhR
d) mice
were obtained from The Jackson Laboratory. SOCS2-deficient
mice were kindly provided by Drs. W.S. Alexander (The Walter
and Eliza Hall Institute for Medical Research, Parkville, Victoria,
Australia). All animals were bred and maintained under pathogen-
free conditions at a Children’s Hospital Medical Center animal
facility (Cincinnati, OH) under a protocol approved by the
Children’s Hospital Medical Center Animal Care and Use
Committee. All experiments shown here were previously approved
under the above protocol.
Infections
T. gondii cysts (ME49 strain) were recovered from brain
homogenates from chronically infected mice and suspended in
PBS. Animals were experimentally infected by intraperitoneal
injection with 20 cysts per mouse in vehicle (0.2 ml/animal). For
in vivo proteasome inhibition, animals received 0.1 mg of PR11
(BIOMOL) i.p. at days 13, 15, 17, 19 and 21 after infection.
Cytokine Determination
IL-12 p70, TNF-a and IFN-c levels were measured using
commercial ELISA kits (BD biosciences). For in vitro experiments,
splenic DCs were partially purified as described [32]. Briefly,
spleens harvested from mice were digested with Liberase CI
(Roche Biochemicals, Indiana, IN). Low-density (LOD) leuko-
cytes were then obtained after centrifugation in a dense-BSA
gradient and CD11c
+ cells were further purified using magnetic
bead-conjugated antibody (Miltenyi Biotech, Auburn, CA). A
representative dot-plot of the cells after purification is shown in
figure S1. After washing in PBS, cells were resuspended in RPMI
10% FCS at 1610
6/ml in 96-well plates (Corning, Corning, NY)
and test stimuli were added as indicated for each experiment. For
in vivo experiments, mice (n=5–10) were infected intraperitone-
ally (i.p.) with 0.2 ml of PBS and 5 and 7 days after infection
were bled for assessment of cytokine levels.
ImageStream Analysis
Spleen-derived CD11c+ dendritic cells (obtained as described
above) were exposed to the following stimulations; LXA4 (3 nM),
Figure 5. LXA4 and L-kynurenine exposure trigger DRE-
mediated gene expression. LacZ transgenic mouse spleen-derived
CD11c+ cells were purified and exposed to medium alone, or with LXA4
(3 nM), L-kynurenine (60 mM) or FICZ (4 mM) for 120 min, followed by
staining with CD11c, CD8a and incubated with the beta-galactosidase
substrate for 1 min at 37uC. Cells were then analyzed by flow cytometry.
Data shown is representative of three independent experiments
performed. Legend indicates the sample identification followed by its
mean fluorescence intensity at the FL1-channel. Histograms were
normalized and presented as % of maximum fluorescence, according to
FlowJo analysis software.
doi:10.1371/journal.pone.0038384.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e38384Figure 6. TRAF6 poly-ubiquitinylation and proteasomal degradation is triggered by DC exposure to LXA4 and L-kynurenine. WT
spleen-derived DCs were cultured in the presence of medium alone (M) or with LXA4 (Lx) (1000 ng/mL), L-kynurenine (Ky) (60 mM) or IL-10 (10)
(100 ng/mL) for 6 hrs. Cells were then homogenized and immuno-precipitated with an anti-TRAF6-agarose-bead mAb. The precipitates were
analyzed by western blot for the presence of TRAF6, poly-ubiquitin (Lys47) and poly-ubiquitin (Lys63). (B) Total TRAF6/beta-actin western blot
analysis in WT DC cell homogenates after incubation with medium alone (M), LXA4 (Lx) (1000 ng/mL) or L-kynurenine (Ky) (60 mM) for the indicated
time points. (C) Time-course, western blot detection of total TRAF6 in spleen-derived cells incubated with LXA4 (3 nM) with or without pre-exposure
to the proteasomal inhibitor PR11 (3 nM for 90 mins). (D) WT spleen-derived cells were incubated with increasing concentrations of IL-10 (black
squares) or LXA4 (red triangles) for 6 hrs, followed by fixation/permeabilization and staining for CD11c and TRAF6 and analyzed by flow cytometry.
Data shown represent plotted MFI’s for TRAF6 staining in CD11c+ cells. (E) WT (squares), SOCS2-KO (triangles) or AhR-deficient (circles) spleen-derived
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38384cells were purified and incubated with medium alone or with increasing concentrations of L-kynurenine (6–60 mM) for 6 hrs, cells were then fixed,
permeabilized and stained for CD11c and TRAF6. The mean fluorescence intensity of TRAF6 staining within CD11c+ cells was then analyzed by flow
cytometry. (F) WT spleen-derived cells were pre-incubated with PR11 (0.03 to 3 nM), followed by incubation with medium alone (filled squares) or
with LXA4 (upright triangles –3 nM), IL-10 (inverted triangles –100 ng/mL), L-kynurenine (diamonds –60 mM), 3-OH-kynurenine (circles –3 mM) and
growth hormone (empty squares –100 ng/mL) for 6 hrs. Cells were then fixed, permeabilized and stained for CD11c, CD8a and TRAF6. Cells were
then analyzed by flow cytometry for their TRAF6 mean fluorescence intensity within the CD11c+CD8a+ subset. Data shown is representative of three
independent experiments performed.
doi:10.1371/journal.pone.0038384.g006
Figure 7. SOCS2 and AhR are required for modulation of host immune response during infection with T. gondii. WT (squares), SOCS2-
KO (triangles) or AhR-deficient (circles) mice (n=8 mice/group) were infected i.p. with 20 cysts of T. gondii (ME49 strain). Animals were monitored for
(A) mortality, (B) cyst formation 30 days after infection, (C) serum levels of IL-12p70 at 5 days after infection and (D) serum levels of IFN-c at day 7 after
infection. (E–F) WT (circles) or SOCS2-KO (squares) mice were infected as described above, from 12 through 30 days after infection animals received
daily i.p. injection of PBS (empty symbols) or 1 mg of PR11 (filled symbols). 30 days after infection, animals (n=3 mice/group) were sacrificed and
antigen-specific CD4+T cell IFN-c production analyzed by intracellular cytokine staining and flow cytometry. Cells were acquired and gated for CD3+
cells, followed by analysis of the frequencies of CD4 versus IFN-c positive cells. The frequencies of IFN-c+ among the total CD3+CD4+ cells are shown
(E). Mortality was monitored throughout the acute and early chronic infection up to 60 days after inoculation (F). Data shown is representative of at
least three independent experiments performed. p values are indicated for statistically significant differences between WT control groups versus
SOCS2-KO or AhR-deficient strains.
doi:10.1371/journal.pone.0038384.g007
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6 cells were
placed in 6 well flat-bottom plates for 2.5 hrs in vitro incubation in
RPMI 10% FCS. The cells were then washed and prepared for
staining. AhR and ARNT (Santa Cruz) primary antibodies were
used to stain cells after stimulation. AlexaFluor 488- and
AlexaFluor 647-conjugated anti-rabbit or rat IgG pAbs were used
as secondary antibodies. Draq5 (Cell Signaling) was used as
nuclear dye. Amnis ImageStream system was used to study AhR
cellular localization and AhR/ARNT molecular interactions.
Flow Cytometry-based Beta-galactosidase Assay
Spleen-derived dendritic cells were purified after collagenase
digestion followed by magnetic bead-conjugated anti-CD11c
purification. Cells were cultured for 1–12 hrs in the presence of
medium alone or FICZ, LXA4, or L-kynurenine (100 ng/ml).
Cells were re-suspended and stained for CD11c, CD8a and
incubated for 1 min at 37uC in the presence of fluorescein di-V-
galactoside (FDG). Cells were acquired in a LSRII cytometer and
analyzed using FlowJo software.
Cell Extracts and Immunoblot Assay
Whole cell extracts were generated by lysing DCs in buffer
containing 50 mM HEPES pH 7.9, 0.25 M NaCl, 5 mM EDTA,
0.1% NP-40, 1 mM PMSF, 16 HALT
TM protease inhibitor
cocktail Pierce Biotechnology Inc. (Rockford, IL). For detection of
phosphorylated-proteins, Na3VO4 and NaF, were added to lysis
buffers. The immunoprecipitation was performed with TRAF6
antibody purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). The detection of protein expression by western blot
was performed with primary antibodies against TRAF6 purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA), poly-
ubiquitin (Lys47) and poly-ubiquitin (Lys 63) mAb’s were
purchased from Millipore.
Real Time RT-PCR
Total RNAwasisolatedfrommurine DC culture using the Trizol
LSreagentaccordingtothe instructionsofthemanufacturer.cDNA
was synthesized with TaqMan Reverse Transcriptase (Applied
Biosystems, Foster City, CA) and mRNA expression of cytokines
(IL-12p35, IL-12p40, IL-23p19, IL-6, IFN-a3 and TNF) – and b-
actin was analyzed by RT-PCR. Real-time RT-PCR was
performed on an ABI-Prism 7000 PCR cycler (Applied Biosystems).
Statistical Analysis
The statistical significance of differences in mean values
between experimental versus control or vehicle treated samples
Figure 8. Increased brain inflammation during chronic T. gondii infection in the absence of SOCS2 and AhR in mice. WT (A, B and G),
SOCS2-KO (C, D and H) and AhR
d (E, F and I) mice were infected as described above. At 30 days after infection, animals were sacrificed, brains (A–F)
and livers (G–I) removed and processed for H&E staining. Circles indicated parasite cysts in brain sections (Panel A). Arrows indicate inflammatory cell
infiltrates. Images are representative of each group (n=3 mice per group). Magnification 106.
doi:10.1371/journal.pone.0038384.g008
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considered to be significant at p,0.05.
Supporting Information
Figure S1 Flow cytometry phenotype of spleen derived dendritic
cells. Spleens were digested with Collagenase D, followed by low-
density gradient. The resulting cell suspensions were labeled with
MACS beads-conjugated anti-CD11c mAb and purified using
MACS columns. Cells were subsequently stained with PacificBlue-
CD11c mAb and analyzed by flow cytometry. The dot plot shows
a typical frequency of total CD11c+ cells obtained using this
protocol.
(TIF)
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